Compare IFS & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IFS | TMDX |
|---|---|---|
| Founded | 1897 | 1998 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.6B |
| IPO Year | 2019 | 2019 |
| Metric | IFS | TMDX |
|---|---|---|
| Price | $49.79 | $130.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $48.00 | ★ $144.25 |
| AVG Volume (30 Days) | 205.7K | ★ 793.9K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | 81.66 | ★ 170.70 |
| EPS | ★ 5.02 | 2.54 |
| Revenue | ★ $1,581,287,530.00 | $566,354,000.00 |
| Revenue This Year | N/A | $38.73 |
| Revenue Next Year | $3.75 | $20.55 |
| P/E Ratio | ★ $10.12 | $53.52 |
| Revenue Growth | 33.10 | ★ 41.20 |
| 52 Week Low | $29.09 | $62.07 |
| 52 Week High | $52.58 | $156.00 |
| Indicator | IFS | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 45.10 |
| Support Level | $47.63 | $132.01 |
| Resistance Level | $52.58 | $139.60 |
| Average True Range (ATR) | 1.60 | 7.29 |
| MACD | 0.21 | -1.05 |
| Stochastic Oscillator | 64.78 | 18.96 |
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services and payments for retail customers and commercial clients in Peru. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services. Its geographical segments include Peru and Panama.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.